arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Tonix Pharmaceuticals Holding Corp.

TNXP
$10.28 ▼ -0.33 (-3.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tonix Pharmaceuticals Holding Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $87.5M
Dividend Yield —
Revenue Growth 29.8% →
Op. Margin —
ROIC -40.5% ↗
FCF / Share $-12.13 ↗
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.11M
↑ +29.8% —
Net Income Profit after all expenses
$-124.02M
↑ +4.6% —
FCF / Share Free cash flow per share
$-12.13
↑ +85.4% —
Long-Term Debt Long-term obligations
$8.65M
↓ -21.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Financial Health ↓
4
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 69 quarters